RecruitingPhase 3NCT06439082
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- Crizanlizumab(biological)
- Enrollment
- 315 enrolled
- Eligibility
- 12-100 years · All sexes
- Timeline
- 2024 – 2030
Study locations (27)
- University Of Alabama, Birmingham, Alabama, United States
- Childrens National Hospital, Washington D.C., District of Columbia, United States
- University of Florida, Jacksonville, Florida, United States
- Augusta University Georgia, Augusta, Georgia, United States
- WCG Sonar Clinical Research, Riverdale, Georgia, United States
- Norton Children s Hospital, Louisville, Kentucky, United States
- The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Southern Specialty Research, Flowood, Mississippi, United States
- Childrens Hospital at Montefiore, The Bronx, New York, United States
- East Carolina University, Greenville, North Carolina, United States
- Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
- Spoknwrdclinicaltrials, Easton, Pennsylvania, United States
- U of TX Health Science Ct, Houston, Texas, United States
- Novartis Investigative Site, Salvador, Estado de Bahia, Brazil
- Novartis Investigative Site, São Luís, Maranhão, Brazil
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06439082 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi